HER Targeting in HER2-Negative Breast Cancers: Looking for the HER3 Positive.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 25609069.
- Also identified by DOI 10.1158/1078-0432.CCR-14-3012 and PMC identifier 4490014.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Targeting HER2 for the treatment of HER2-positive breast cancers is now a validated treatment paradigm. However, evidence suggests that this family of receptors may have important roles outside of the realm of HER2 amplification. There is considerable interest in the development of biomarkers to identify such breast cancers.
Medical subject headings
- Antineoplastic Agents
- Breast Neoplasms
- Carcinoma, Ductal, Breast
- Quinazolines